Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Moderna Inc (NASDAQ: MRNA) closed the day trading at $121.89 up 0.68% from the previous closing price of $121.07. In other words, the price has increased by $0.68 from its previous closing price. On the day, 2.51 million shares were traded. MRNA stock price reached its highest trading level at $122.82 during the session, while it also had its lowest trading level at $119.5.
Ratios:
For a better understanding of MRNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.91 and its Current Ratio is at 4.03. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’24 when AFEYAN NOUBAR sold 15,000 shares for $110.92 per share. The transaction valued at 1,663,855 led to the insider holds 2,026,931 shares of the business.
AFEYAN NOUBAR sold 15,000 shares of MRNA for $1,624,836 on Apr 24 ’24. The Director now owns 2,041,931 shares after completing the transaction at $108.32 per share. On Apr 17 ’24, another insider, AFEYAN NOUBAR, who serves as the Director of the company, sold 15,000 shares for $103.38 each. As a result, the insider received 1,550,703 and left with 2,056,931 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 46713122816 and an Enterprise Value of 39112835072. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.08 while its Price-to-Book (P/B) ratio in mrq is 3.64. Its current Enterprise Value per Revenue stands at 7.59 whereas that against EBITDA is -8.577.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $142.79, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 15.10%, while the 200-Day Moving Average is calculated to be 23.87%.
Shares Statistics:
Over the past 3-months, MRNA traded about 3.98M shares per day on average, while over the past 10 days, MRNA traded about 4145340 shares per day. A total of 382.00M shares are outstanding, with a floating share count of 336.72M. Insiders hold about 12.14% of the company’s shares, while institutions hold 67.57% stake in the company. Shares short for MRNA as of 1713139200 were 20981181 with a Short Ratio of 5.28, compared to 1710460800 on 22227123. Therefore, it implies a Short% of Shares Outstanding of 20981181 and a Short% of Float of 7.22.
